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ABSTRACT
Objective: To examine antenatal screening as a predictor ofintrapartum shedding of herpes simplex
virus (HSV) and to determine its usefulness in guiding the appropriate route of delivery for patients
with recurrent HSV in pregnancy.
Methods: A population of 198 pregnant women with a history of recurrent genital HSV were
cultured in the last weeks of their pregnancy by specially-trained personnel and intrapartum by
their delivering attendants.
Results: Of cultures from a total of 906 antenatal visits, 17% were culture positive, with an
asymptomatic shedding rate of 3.4%. Asymptomatic shedding occurred in 12.6% of women. Over
the 8-week antepartum period, viral culture-positivity rates for each visit ranged from 11% to
19.5%. This provided an expected delivery culture-positivity rate of 15.3%. However, actual intra-
partum viral culture positivity occurred in only three of 191 women (1.5%; P < 0.001). Because
previous studies have suggested antepartum culture positivity fails to predict intrapartum viral
shedding, evaluations, including cultures, as well as predictive values for subsequent culture posi-
tivities, were determined under the supervision of an infectious disease specialist. Under these
conditions, positive predictive values were 59% when the interval between visits was 2 days, but
only 19% when days between visits were >2 (P < 0.0001). No cases of neonatal herpes were seen
in this population, although cesarean deliveries were performed in 31% of the patient population,
with genital herpes as the indication for 56% of those.
Conclusions: Antepartum serial screening by viral culture is not predictive of an infant’s risk of
intrapartum viral exposure when conducted at weekly intervals. However, more frequent assess-
ments of patients can be predictive of an infant’s exposure risk to HSV; for patients with frequent
recurrent disease near term or primary infection in pregnancy, frequent late antepartum screening
may be appropriate. Infect. Dis. Obstet. Gynecol. 7:230-236, 1999. (C) 1999 Wiley-Liss, Inc.
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eonatal herpes simplex virus (HSV) infection
is largely acquired intrapartum and, even with
prompt recognition and treatment, is associated
with significant morbidity and mortality.
1-3 Mater-
nal infection is unrecognized in the majority of
cases.4,s In an attempt to reduce the incidence of
this disease, the American Academy of Pediatrics
in 1980 recommended serial viral screening in the
last weeks of pregnancy for all women with a past
history of genital herpes.6 Avoidance of vaginal de-
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livery was recommended to prevent transmission of
virus to the infant in the setting of either clinical or
virologic evidence of active infection. Arvin et al.,
however, demonstrated that weekly antepartum
cultures in the third trimester were not actually
predictive of asymptomatic intrapartum shedding.7
This has led to revision of the guidelines, with the
elimination of serial antepartum viral screening.8
Further arguments against serial screening of
symptomatic patients include the premise that
most women with genital HSV are infected sub-
clinically. Furthermore, Brown et al. have demon-
strated that neonatal risk is highest in the setting of
recent acquisition of infection.9 In fact, Randolph
et al. have recently suggested the elimination of
cesarean delivery for active recurrent disease intra-
partum.
1 Nevertheless, recommendations of these
authors have not been widely accepted as yet,
1
and recurrent disease still accounts for up to 50% of
neonatal cases. Hence, the current management of
patients with recurrent genital herpes remains un-
settled, the decision regarding cesarean delivery
being largely left to clinical judgment regarding
evident symptomatic lesions in labour. As a com-
promise, some investigators have chosen to sup-
press recurrences with oral acyclovir during the fi-
nal 2-4 weeks of gestation,z,3 hoping to avoid ce-
sarean deliveries.
During the mid-1980s, a group of patients con-
sidered at high risk for genital herpes were referred
to a university teaching hospital clinic for prenatal
assessment and follow up. Because of the recent
changes in our understanding of the pathogenesis
of neonatal infection, we analysed data collected
from that period to extend our understanding of
the natural history of the disease. We report here
our experience of antenatal screening to predict
intrapartum shedding and its value in guiding the
appropriate route of delivery for patients with re-
current herpes in pregnancy.
METHODS
Patient Population
The study population consisted of 198 pregnant
women referred from May 1985 to July 1987 to the
University of British Columbia Herpes Clinic, Van-
couver, Canada, by their local medical practitioners
because the women had a previous history of geni-
tal HSV, previous genital culture positive for HSV,
or their partners had a history of HSV. After written
consent was obtained, patients completed a ques-
tionnaire detailing patient demography, pregnancy
and sexual history, and past sexually-transmitted-
disease history with detailed questioning for oral
and genital herpes (including a photographic ques-
tionnaire). Serum was obtained from each woman
at initial assessment for HSV type-specific antibod-
ies.
Clinical evaluation of patients occurred at weeks
32, 34, and 36 of gestation and weekly to delivery
according to standard practice at that time. Evalu-
ations were performed by an infectious disease spe-
cialist, and at each visit symptoms and signs of any
recent genital HSV were documented. In addition,
cultures were taken from any apparent clinical le-
sion(s), or, if no lesions were present, a general
sweep from the external genital area (a Dacron-
tipped metal swab previously moistened in normal
saline was wiped firmly over the pubic area, clitoris,
periurethral area, labia minora and majora, four-
chette, perineal and perianal areas), and a separate
swab was also collected from the ectocervix.
At the conclusion of each visit, a recommenda-
tion was made to the attending physician as to the
ideal mode of delivery. Where no clinical disease
was evident, vaginal delivery was recommended,
whereas for an active episode (symptomatic/
asymptomatic), cesarean delivery was considered
the ideal delivery mode, if labour intervened. For
those with an active episode antepartum, more fre-
quent follow up of the patient was arranged at the
Herpes Clinic, until a return to a culture-negative
and asymptomatic clinical status was achieved. At
birth, repeat cultures (as described above) were
performed of the upper and lower genital tract by
the attending obstetrician or physician. In addition,
the fresh placenta, the infant (mouth, axilla, groin),
and, in the case of those delivered by cesarean de-
livery, amniotic fluid, were also cultured for HSV.
A research nurse collected individual patient de-
tails in labour and baby outcome at birth, as well as
follow up at 6 weeks postpartum, with a telephone
call to parents to inquire regarding the baby’s
health.
Viral Culture
After sampling, swabs were placed into viral trans-
port medium which consisted of Medium 199 with
Hank’s balanced salt solution containing 1% inac-
tivated fetal calf serum plus antibiotics (penicillin,
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streptomycin, and amphotericin B). Specimens
were transported daily for inoculation in duplicate
onto human foreskin fibroblast monolayers and
processed by standard rnethods. 14 Monolayers were
examined daily for development of cytopathic ef-
fects, when they were stained with HSV type-spe-
cific monoclonal antibodies (Syva, Palo Alto, CA) for
confirmation and typing as previously described. 15
Viral Serology
Antibodies to HSV (type specific) were detected
by microneutralization and Western blot assay.
6
RESULTS
Demographic details of the patient population are
outlined in Table 1. For the 8-week antepartum
period during which the 198 patients were regu-
larly assessed clinically and by culture, 906 total
visits were made. For the total visits, 884 had com-
pleted data for both symptoms and signs, whereas
for symptoms or for signs, 898 and 903, respectively
(Table 2). The median and mean number of visits
were 4.0 (interquartile, 3-6) and 4.6 (standard de-
viation [SD], 2.6), respectively; the median interval
between visits was 7.0 days (interquartile, 4-9),
mean, 8.2 (SD, 9.9). Between the last antenatal
visit to delivery, the median number .of .days was
4.0 (interquartile, 2-8), mean, 8.9 (SD, 27.8). Over-
all 88.7% of patients were positive by Western blot
for HSV type-2 antibodies (with or without HSV
type-1 antibodies); 62% were positive for HSV
type-2 antibodies alone, and 8.7% were positive for
HSV type-1 alone, a6
Of the 198 patients, 191 had at least one follow-
up visit. Details of clinical lesions and of culture
results for all the antepartum visits and of the ul-
timate visit prior to delivery are depicted in Table
2. It is evident that symptoms were reported in
20% and signs consistent with HSV evident in 28%
of all visits, whilst 17% of all visits were positive by
culture. Overall, 94 patients (48%) had HSV con-
firmed by culture (for 154 visits), and 97% of these
isolates were HSV type 2. Patients were either
symptomatic (as defined by prodrome, redness,
blister, ulcer, or crust) or had signs consistent with
HSV (macule, papule, vesicle, pustule, or ulcer) in
89% of these visits. Twenty-four women (12.6%)
shed HSV asymptomatically. Six of these women
shed on two occasions. Therefore, the asymptom-
atic shedding rate for the total antepartum visits
TABLE I. Demographic characteristics of the
pregnant population
Variable n (+SD) %
Age at st pregnancy 26.3 + 5.3
Age at st sexual contact 18. + 2.7
Number of lifetime sexual partners 14.6 + 8.5
Age at enrollment (years) 31. + 4.3
Number of previous pregnancies
0 82 41.4
I-3 107 54.5
>3 7 3.6
Marital status
Never married 13 6.9
Married/common-law 171 90.5
Divorced/separated 4 2.
Widowed 0.5
Racial background
Caucasian 182 95.3
Black 0 0
Other 9 4.7
Income (thousand dollars)
<25 43 23.0
25-49.9 88 47.1
>50 56 29.9
Education
High school or less 25 13.2
Some technical school 24 12.7
Some university 140 74.
Personal history of genital herpes
Yes 168 88.4
No 4 2.1
Maybe 18 9.5
History of oral cold sores
Yes 67 35.3
No 109 57.3
Maybe 14 7.4
Sex with known HSV-infected person
No 65 36.3
I-2 times 48 26.8
Often 66 36.9
Previous Sexually Transmitted Disease
Yes 54 27.8
No 142 72.2
was 3.4% (30/884). Of these 30 asymptomatic shed-
ding episodes, 86.7% (26) were from the external
anogenital area, and 3.4% (1) were from the cervix,
while the remainder were from the usual lesion
site. The patient who shed from the cervix also
shed from the external anogenital area of the labia.
Twenty-five percent (6/24) of those women with
asymptomatic shedding had no signs or symptoms
of genital herpes for at least 4 weeks (mean, 27
days; range, 7-72) prior to the positive culture.
Similarly, most subjects with asymptomatic shed-
ding (66.4% [16/24]) did not have subsequent
symptoms or signs of genital HSV. Of the 33.3%
(8/24) who did subsequently have symptoms or
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TABLE 2. Description of findings at antenatal visits
Total Final
antenatal visits antenatal visit
Variable n % n %
Total prenatal visits 906 19
Symptoms of herpes 182/898 20.3 26/191 13.6
Signs of herpes 251/903 27.8 30/I 90 15.8
Lesion site frequency
Cervix 0. 0 0
Labia majora 88 10.7 II 6.4
Labia minora 32 3.9 2 1.2
Perineal 28 3.4 4 2.3
Perianal 30 3.7 4 2.3
Buttocks 33 4.0 5 2.9
Other genital 43 5.2 4 2.3
Remote sites 13 1.6 3 1.7
Lesion stage
Macule 4.2 4 12.
Papule 20 7.7 3.0
Vesicle 18 6.9 2 6.
Pustule 22 8.5 2 6.
Ulcer 119 45.8 13 39.4
Crust 33 12.7 4 12.
Healed 37 14.2 7 21.2
Positive culture, any sites 154/906 17.0 16/191 8.4
Genital culture positive 121/892 13.4 10/188 5.2
Cervix culture positive 3/756 0.3 I/I 74 0.5
Usual skin site positive 25/83 2.9 5/15 2.7
Asymptomatic shedding rate 30/884 3.4
aDelivery details only available for 191 patients.
signs (mean, 12.6 days; range, 2-44), six (75%) were
culture positive.
As depicted in Figure 1, the ability of an ante-
partum culture positive for HSV to predict a sub-
sequent positive result (i.e., positive predictive
value) was 59% (30/51) when the interval between
visits was -<2 days, but only 19% (53/257) when
days between visits were >2 (P < 0.0001). Clinical
evidence of HSV was less predictive of a subse-
quent positive culture result. When the interval
between visits was -<2 days, clinical prediction of a
positive culture (i.e., positive predictive value) was
40% (27/67), whereas it was 17% (59/355) for >2
days (P < 0.0001).
At the final antenatal visit before labour, symp-
toms were reported in 13.6%, whilst signs of HSV
were evident in 15.8%, and cultures were positive
in 8.4% (Table 2). Intrapartum, a similar number of
women reported symptoms (11.5%), and signs were
evident on clinical examination in 9.5%. However,
cultures taken by the patients’ attending physician
intrapartum were positive in only 1.5% (3/191) of
cases (Table 3). All t.hree had previous signs and
symptoms of HSV and were Western-blot-positive
for HSV type 2 antibodies, and two were culture
positive antepartum. In two of these cases, patients
reported symptoms of herpes in labour, and active
herpetic lesions were evident on exam. Both cases
were delivered by cesarean delivery with a favour-
able outcome. The third case was asymptomatic at
term and was delivered vaginally without adverse
outcome. Of the 24 women who had asymptomatic
excretion of HSV during pregnancy, three had
signs or symptoms intrapartum, and none were cul-
ture positive.
The results of HSV culture positivity for the
final six antepartum visits (as collected by the staff
of the Herpes Clinic) together with the actual rate
at delivery (as collected by the patients’ own care
provider) are shown in Table 3. As the intrapartum
culture rate (1.5%) is at variance with the foregoing
antepartum weekly rates (11.4-19.5%), an esti-
mated intrapartum positivity was calculated based
on these antepartum results. Two methods of es-
timation were performed. A crude estimate was
made by taking an average percentage of the cul-
ture-positive rate of the previous six visits and was
found to be 16.1%. The second estimate was a
weighted average of the probability of culture posi-
tivity for each patient at delivery, based on the
number of their previous visits. These probabilities
were weighted by the number of visits for each
patient, then the average was calculated. The an-
ticipated delivery culture-positivity rate was calcu-
lated at 15.3% had the Herpes Clinic staff taken
these specimens. Calculations were adjusted to
eliminate any selection bias; i.e., assessment was
only made for those patients initially negative by
culture who became positive. Cases positive at the
initial antepartum assessment were excluded. All
analyses were carried out using a Statistical Analy-
sis System.
For antepartum visits that occurred within 7
days of delivery (130), viral shedding occurred in 13
(10%) (Table 4). The asymptomatic shedding rate
of these visits was 3%. Of those advised to have a
cesarean delivery on the basis of active lesion or
positive HSV cultures, 85% (11/13) delivered by
this method. Overall, cesarean deliveries were per-
formed for 31% of patients, with genital HSV being
the indication in 56%. Recommended delivery
plans based on the antepartum screening highly
correlated with the actual delivery method and the
culture results of the final antepartum assessment
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Fig. I. Predicting HSV shedding from the genital tract. Positive predictive value (PPV) (,) of culture as the predictor. Positive
predictive value (O) of clinical assessment is. the predictor of herpes shedding from the genital tract in subsequent patient visit.
TABLE 3. Actual and estimated culture positivity at
delivery based on previous antepartum follow up
No.
symptomatic/total
No. positive HSV
Visit positive/total % isolations %
6 8/42 19.5 7/8 87.5
5 9/57 15.8 6/9 66.8
4 16/75 21.3 I/I 6 68.8
3 10/91 1.0 7/10 70.0
2 18/101 17.8 12/18 66.8
12/105 1.4 0/I 2 83.3
Delivery 3/191 1.5" 2/3
Estimated at delivery
Crude 3 I/I 91 16. I* 22/31 71.0
Weighted 29/I 91 15.3* 22/29 79.0
*P < 0.001 (trend estimate).
(P < 0.001) (Table 4). There were no cases of neo-
natal herpes detected, and all baby and placental
swabs taken at delivery were negative by viral cul-
ture.
DISCUSSION
In this patient population with histories of recur-
rent genital herpes, the observed culture-positivity
rate for HSV for the 6-week period prior to delivery
was consistently high, ranging from 11% to 19.5%.
An unexpected finding in this study was the low
culture-positivity rate when nonspecialized person-
nel took genital swabs for culture. This unantici-
pated occurrence confounded the intrapartum cul-
TABLE 4. Comparison between findings at final
antepartum (-<7 days) visit to recommended and
actual delivery plan
Last plan for mode of delivery
Plan Plan 2 Plan 3
Variable n % n % n % P value
Culture at the last visit
Negative 9.4 12 10.3 94 80.3
Positive 84.6 0 0.0 2 15.4
Actual delivery
Vaginal 4 4.6 4 4.6 79 90.8
Cesarean 18 43.9 8 19.5 15 36.6
<0.001
<0.001
aPlan I" Cesarean until change in HSV status.
Plan 2: Cesarean until culture negative at specified week of gestation.
Plan 3: Normal vaginal delivery.
ture rate, which was at variance with the preceding
antepartum shedding rate of herpes for the patient
population. Only three patients were culture posi-
tive intrapartum and two of these in fact had clini-
cal lesions and were delivered by cesarean delivery
accordingly. The third patient shed HSV asymp,
tomatically and delivered vaginally; her baby was
culture negative and had a good outcome.
Over the 8-week antepartum period, symptoms
consistent with HSV occurred in 20% of visits, and
these were culture positive in 55.7%. These find-
ings are similar to those reported by Vontver,
where 56% of recurrent clinical lesions were cul-
ture positive. 17 In our study group, 17% of antepar-
turn visits were culture positive and the asymptom-
atic shedding rate was 3.4% (external genital,
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96.6% cervical, 3.4%). Overall, 12.6% of patients
shed asymptomatically antepartum. This figure
contrasts W’ith that of other similar studies in which
asymptomatic excretion has been reported in ante-
partum patients at around 4% and at a shedding
rate of 0.35-0.75%. 18 We believe this tenfold dif-
ference in shedding detection relates predomi-
nantly to expert personnel taking the clinical
samples rather than others. This is further sup-
ported by the unexpectedly low intrapartum shed-
ding rate (samples collected by delivery ward staff)
found in our study, compared with that anticipated
by antepartum rates (samples collected by person-
nel experienced in infectious disease). A further
explanation for these findings may be the dilution
effect on viral load by the flushing effect of amni-
otic fluid following rupture of the chorioamniotic
membranes. The actual rate of shedding intrapar-
turn of 1.5% for this study is similar to those pre-
viously reported (range, 0.35-2.4%).7,18’9
No cases of neonatal herpes were seen in this
study and no babies cultured positive at birth. The
overall cesarean delivery rate was 31%, HSV being
the indication in 56%. The recommendation to de-
liver by cesarean delivery, based on the last ante-
partum visit culture, correlated well with the actual
delivery mode. Of those cultured within 7 days
prior to delivery, 10% were positive (13/130), and
84.6% (11/13) who had been advised to have a ce-
sarean delivery on these grounds complied.
Data from our study confirm the findings of
Arvin et al. 7 that early preterm weekly cultures
from patients are not helpful in predicting shed-
ding at delivery. Those data were obtained by cli-
nicians in the field, which, in light of our findings,
may not have been a sensitive marker. Further,
their finding of lack of predictability is not surpris-
ing and reflects inherent problems with HSV cul-
ture, which, at best, takes 48 hours to produce a
result. Also, recurrent lesions shed for a short time
(3-4 days); consequently, by the time a result is
obtained from a laboratory, it poorly reflects the
situation at that time. However, our study did show
that antepartum exams were highly predictive of
subsequent outcome where visits between predic-
tion and outcome were 2 days but not predictive
when the interval between visits was more than 2
days. Therefore, we believe that appropriately and
carefully collected antepartum serial cultures may
still have a role in selected patients, i.e., those suf-
fering frequent recurrences near term. In this sce-
nario, viral cultures every few days to demonstrate
cessation of viral shedding could obviate the need
for cesarean delivery.
The neonatal attack rate for women who deliver
vaginally in the presence of recurrent genital HSV
lesions is very low, on the order of <2%.z In con-
trast, women with primary genital HSV near or at
delivery have a neonatal transmission rate 35-
80%.4’9’10’21 With such a very low rate of neonatal
HSV from recurrent maternal infections, some ad-
vise covering genital lesions and allowing delivery
vaginally as, the morbidity of cesarean delivery is
greater, l,zz Yet, cervical shedding in association
with recurrent external HSV lesions, although less
frequent to primary infections (85%) is reported to
occur in 12-16% of cases,z3 Moreover, as neonatal
HSV carries the risk of significant morbidity and
mortality, even with acyclovir treatment, we be-
lieve, as do others,z4 that cesarean delivery is the
appropriate form of delivery when clinical maternal
genital lesions are apparent.
Asymptomatic shedding data from our study
are consistent with the findings of Wald et al. in a
nonpregnant population, zs They also demon-
strated a much higher frequency of reactivation
based on detection by polymerase chain reaction.
Accordingly, wide inconsistency exists in any
management strategy that requires recognition of
symptoms. Some studies have adopted acyclovir
suppression, now established to reduce both symp-
tomatic and asymptomatic viral shedding rates out-
side of pregnancy, as an alternative strategy. Un-
fortunately, definitive answers regarding efficacy
against both maternal shedding and neonatal infec-
tion are not yet available. Furthermore, while the
safety of acyclovir in pregnancy is likely, it is un-
proven. In our view, there is little reason to doubt
that acyclovir will predictably, but not incom-
pletely, suppress viral shedding and symptomatic
recurrent infection in pregnancy and, therefore,
will likely reduce cesarean delivery rates for
women with high recurrence frequency rates. This
would appear to offer a strong cost benefit and
would potentially obviate surgical morbidity while
we continue to pursue neonatal infection risk fac-
tors. However, neonatal infection has occurred in
the setting of inadequate maternal acyclovir sup-
pression therapy. Clearly, properly conducted, pla-
cebo-controlled, randomised trials stratified accord-
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ing to type-specific immune status and frequency
rates are warranted before new recommendations
are made.
Finally, it is essential to recognise that current
medical practice does not directly address the
group at highest risk for neonatal transmission:
HSV-susceptible women in the third trimester who
are in HSV discordant relationships.9 Only routine
serologic screening of both partners can begin to
address prevention in this highest-risk patient.
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